Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reneo Pharmaceuticals (RPHM)
NASDAQ:RPHM
Holding RPHM?
Track your performance easily
RPHM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.80 - $92.10
Previous Close$18.65
Volume437.52K
Average Volume (3M)17.20K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$76.67M
Total Debt (Recent Filing)$823.00K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Nov 06, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.85
Shares Outstanding33,428,808
10 Day Avg. Volume35,314
30 Day Avg. Volume17,202
Standard Deviation0.29
R-Squared0.00129
Alpha-0.00763
Financial Highlights & Ratios
Price to Book (P/B)7.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Reneo Pharmaceuticals News
PremiumCompany Announcements
Reneo Pharmaceuticals: Navigating Financial Challenges and Corporate Changes
PremiumCompany Announcements
Reneo Pharmaceuticals Announces Merger and Executive DeparturePremiumCompany Announcements
Reneo Pharmaceuticals Announces Merger and Strategic PIPE InvestmentRisk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RPHM FAQ
What was Reneo Pharmaceuticals’s price range in the past 12 months?
Reneo Pharmaceuticals lowest stock price was $9.80 and its highest was $92.10 in the past 12 months.
What is Reneo Pharmaceuticals’s market cap?
Currently, no data Available
When is Reneo Pharmaceuticals’s upcoming earnings report date?
Reneo Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is 17 days ago.
How were Reneo Pharmaceuticals’s earnings last quarter?
Reneo Pharmaceuticals released its earnings results on Aug 13, 2024. The company reported -$1.6 earnings per share for the quarter, missing the consensus estimate of -$1 by -$0.6.
Is Reneo Pharmaceuticals overvalued?
According to Wall Street analysts Reneo Pharmaceuticals’s price is currently Overvalued.
Does Reneo Pharmaceuticals pay dividends?
Reneo Pharmaceuticals does not currently pay dividends.
What is Reneo Pharmaceuticals’s EPS estimate?
Reneo Pharmaceuticals’s EPS estimate is -$0.7.
How many shares outstanding does Reneo Pharmaceuticals have?
Reneo Pharmaceuticals has 3,342,881 shares outstanding.
What happened to Reneo Pharmaceuticals’s price movement after its last earnings report?
Reneo Pharmaceuticals reported an EPS of -$1.6 in its last earnings report, missing expectations of -$1. Following the earnings report the stock price went up 2.985%.
Which hedge fund is a major shareholder of Reneo Pharmaceuticals?
Among the largest hedge funds holding Reneo Pharmaceuticals’s share is Highbridge Capital Management LLC. It holds Reneo Pharmaceuticals’s shares valued at 44M.
---
Reneo Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
RPHM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 178.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.42%
12-Months-Change
Fundamentals
Return on Equity
-54.00%
Trailing 12-Months
Asset Growth
-46.83%
Trailing 12-Months
Company Description
Reneo Pharmaceuticals
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
RPHM Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Foghorn Therapeutics
―
Heron Therapeutics
―
Seres Therapeutics
―
Praxis Precision Medicines
―
Best Analysts Covering RPHM
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-52.00%
reiterated a sell rating 8 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.00% per trade.
---